๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Czechia
Clinical trial register · European Union · CTIS

Clinical Trials in Czechia, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12479 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 24 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,479
Total on CTIS
full historical archive
743
Phase III
within the shown window
Top member states
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531
Narrow the registerReset
Phase
Phase I 555 Phase I/II 212 Phase II 730 Phase III 743 Phase IV 260
Lead sponsor
AstraZeneca AB 63 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531 Belgium 431 Czechia 331
All 28 states

Trials with a site in Czechia

331 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
2025-524367-20-00Adult patients with primary mitochondrial disease
Pharming Technologies B.V.
Metabolism
Belgium, Germany, Czechia, Spain, Denmark, Italy, France
21/05/2026
Phase III
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib
2025-524078-40-00Chronic Spontaneous Urticaria
Novartis Pharma AG
Skin and Connective Tissue Diseases
Germany, Spain, France, Poland, Bulgaria, Czechia
20/05/2026
Phase III
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
2025-523259-72-00Hidradenitis Suppurativa (HS)
Novartis Pharma AG
Immune System Diseases
Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy
20/05/2026
Phase II
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
2025-524005-32-00Rheumatoid arthritis
Elevara Medicines Limited
Immune System Diseases
Czechia, Bulgaria, Hungary, Netherlands, Poland, Spain
19/05/2026
Phase III
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
2025-521632-12-00Patients on Factor Xa inhibitor treatment needing an urgentโ€ฆ
VarmX B.V.
Hemic and Lymphatic Diseases
Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania
19/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
2025-524316-11-00Primary Progressive Multiple Sclerosis (PPMS)
Zenas Biopharma (USA) LLC
Nervous System Diseases
Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary
18/05/2026
Phase III
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 โ‰ฅ 50%
2025-523586-18-00Non-Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia
15/05/2026
Phase III
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
2025-523389-26-00Relapsed/refractory primary central nervous system lymphoma
Deciphera Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary
14/05/2026
Phase III
A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.
2025-523869-22-00advanced or metastatic extrapulmonary neuroendocrine carcinโ€ฆ
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway
13/05/2026
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
2025-523106-32-00Obesity or Overweight and Type 2 Diabetes
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Germany, Romania, Czechia, Poland, Hungary, France, Spain, Italy
13/05/2026
Phase II
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F
2026-525213-31-00Esophageal squamous cell carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Germany, France, Norway
12/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
2025-521950-41-00severe uncontrolled asthma
Generate Biomedicines Inc.
Respiratory Tract Diseases
Latvia, Hungary, Bulgaria, Romania, Portugal, Netherlands, Croatia, Germany, Greece, Czechia
12/05/2026
Phase III
DAREONยฎ-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
2025-520565-51-00small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary
12/05/2026
Phase III
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naรฏve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
2025-522586-30-00Psoriatic Arthritis
Takeda Development Center Americas Inc.
Musculoskeletal Diseases
Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy
12/05/2026
Phase III
A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)
2025-524265-24-00Dyslipidemia at High to Very High Cardiovascular Risk
A. Menarini International Licensing S.A.
Hemic and Lymphatic Diseases
Spain, Poland, Netherlands, Italy, Slovakia, Czechia, Germany
11/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
2025-522854-37-00Prevention of a Major infection in patients with Hypogammagโ€ฆ
Octapharma Pharmazeutika Produktionsgesellschaft mbH
Immune System Diseases
Czechia, Lithuania, Greece, Poland, Germany, Latvia, Bulgaria, Italy
11/05/2026
Phase III
J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
2025-522255-25-00Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neopโ€ฆ
Eli Lilly & Co.
Neoplasms
Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany
11/05/2026
Phase III
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
2025-522983-33-00Chronic rhinosinusitis with nasal polyps
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland
11/05/2026
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
2025-523104-71-00Obesity or Overweight Without Type 2 Diabetes
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain
07/05/2026
Phase I
Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects
2025-524376-36-00short-term treatment of insomnia
Orion Corporation
Nervous System Diseases
Czechia
05/05/2026
Phase III
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
2025-523443-35-00Persistent Corneal Epithelial Defect (PCED)
Dompe' Farmaceutici S.p.A.
Eye Diseases
Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France
05/05/2026
Phase II
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
2025-524001-33-00Gravesโ€™ Disease
Immunovant Sciences GmbH
Immune System Diseases
Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia
05/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes
2025-523486-17-00Obesity
Kailera Therapeutics Inc.
Nutritional and Metabolic Diseases
Bulgaria, Hungary, Spain, Germany, Czechia, Poland
05/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
2025-523552-31-00Systemic Lupus Erythematosus
Janssen Cilag International
Immune System Diseases
Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland
05/05/2026
Phase II
A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
2025-523704-77-00Geographic atrophy secondary to age-related macular degenerโ€ฆ
Novartis Pharma AG
Eye Diseases
Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France
04/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes
2025-523510-87-00Obesity
Kailera Therapeutics Inc.
Nutritional and Metabolic Diseases
Hungary, Poland, Bulgaria, Germany, Czechia, Spain
04/05/2026
Phase III
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy
2024-519638-22-00IgA nephropathy
Novartis Pharma AG
Immune System Diseases
Belgium, France, Czechia, Croatia, Greece, Germany, Italy, Spain
04/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)
2024-516993-31-00Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece
04/05/2026
Phase I
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis
2025-524205-32-00Atopic Dermatits
Regeneron Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Germany, Poland
30/04/2026
Phase III
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
2024-520218-23-00Pulmonary Arterial Hypertension
Inhibikase Therapeutics Inc.
Cardiovascular Diseases
Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania
28/04/2026
Phase III
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Longโ€‘term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
2025-524160-38-00Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMโ€ฆ
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark
28/04/2026
Phase III
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases
2025-524498-17-00Pretreated Unresectable Locally Advanced or Metastatic humaโ€ฆ
F. Hoffmann-La Roche AG
Neoplasms
Belgium, France, Italy, Austria, Romania, Poland, Portugal, Czechia, Germany, Spain, Hungary
28/04/2026
Phase III
A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D
2025-522750-39-00Erosive esophagitis (EE) due to gastroesophageal reflux disโ€ฆ
Cinclus Pharma Holding AB (publ)
Digestive System Diseases
Hungary, Germany, Romania, Bulgaria, Czechia, Poland
28/04/2026
Phase I
Safety of stem cells in treatmemt of retinal diseases.
2023-503573-38-00Retinal degenerative diseases
Bioinova a.s.
Eye Diseases
Czechia
28/04/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)
2023-508047-40-00Ovarian cancer
Merck Sharp & Dohme LLC
Neoplasms
Norway, Ireland, Spain, Greece, France, Poland, Denmark, Austria, Hungary, Belgium, Czechia, Finland, Germany, Italy, Sweden
28/04/2026
Phase III
Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
2025-522552-20-00Lennox-Gastaut Syndrome
Epygenix Therapeutics Inc.
Nervous System Diseases
Italy, Spain, Hungary, Romania, Czechia, Poland
28/04/2026
Phase III
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimerโ€™s Disease Dementia
2024-517388-22-00Agitation in Alzheimer's Disease Dementia
Exciva GmbH
Nervous System Diseases
Italy, Slovakia, Spain, Poland, Czechia, Germany
28/04/2026
Phase II
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis
2024-514246-37-00Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania
27/04/2026
Phase III
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)
2024-519298-21-00Cancer-Associated Thrombosis (CAT).
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Belgium, Czechia, France, Romania, Germany, Poland, Bulgaria, Spain
27/04/2026
Phase II
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab
2024-518858-17-00Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLโ€ฆ
AstraZeneca AB
Neoplasms
Italy, Austria, Spain, Ireland, Czechia, Poland
27/04/2026
Phase I/II
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
2025-522019-40-00relapsed or refractory BCR::ABL1-positive (Philadelphia posโ€ฆ
Novartis Pharma AG
Neoplasms
Italy, Spain, Germany, Netherlands, France, Denmark, Czechia
27/04/2026
Phase I
Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
2026-526102-33-00No medical condition
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
24/04/2026
Phase III
J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
2025-523659-73-00Obesity, Overweight
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Spain, Romania, Belgium, Czechia
21/04/2026
Phase I
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogrenโ€™s Disease or Idiopathic Inflammatory Myopathy
2025-524100-29-00Seropositive autoimmune disease: Sjogrenโ€™s disease or idiopโ€ฆ
Ouro Medicines Limited
Immune System Diseases
Czechia
21/04/2026
Phase III
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
2025-524366-21-00treatment-naive Chronic Lymphocytic Leukemia
BeOne Medicines I GmbH
Neoplasms
Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden
20/04/2026
Phase II
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochroโ€ฆ
CSL Behring LLC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands
20/04/2026
Phase I
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
2024-520125-36-00Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloโ€ฆ
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Hungary, Czechia, France, Italy, Belgium
20/04/2026
Phase III
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
2025-522855-25-00Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neโ€ฆ
Eli Lilly & Co.
Neoplasms
Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain
20/04/2026
Phase III
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
2025-523717-29-00HFpEF or HFmrEF and obesity
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase I/II
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors
2025-521911-38-00Advanced HR+/HER- breast cancer
Novartis Pharma AG
Neoplasms
Italy, Germany, France, Czechia, Denmark, Spain
16/04/2026
Phase III
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)
2025-523975-48-00Obesity
Metsera Inc.
Nutritional and Metabolic Diseases
Czechia, Bulgaria, Slovakia, Spain, Hungary, Germany, Romania, Poland
16/04/2026
Phase III
A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease
2024-518835-13-00Suspected Vascular Disease of supra-aortic (carotid/vertebrโ€ฆ
Guerbet, Bracco Imaging S.p.A.
Cardiovascular Diseases
Italy, France, Czechia, Hungary, Spain, Germany, Poland
15/04/2026
Phase II
C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
2025-522965-31-00Atopic Dermatitis
Pfizer Inc.
Skin and Connective Tissue Diseases
Poland, Czechia, Germany, Bulgaria, France
14/04/2026
Phase III
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
2025-524038-24-00Focal Epilepsy
Praxis Precision Medicines Inc.
Nervous System Diseases
Poland, Germany, Czechia, Italy, Spain
10/04/2026
Phase III
Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis
2024-511593-70-00Polyarticular-course juvenile idiopathic arthritis
Alfasigma S.p.A.
Musculoskeletal Diseases
Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia
07/04/2026
Phase III
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER RANDOMIZED, CONTROLLED TRIAL (VESPER-4)
2025-523974-18-00Obesity
Metsera Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Slovakia, Poland, Spain, Czechia, Romania, Bulgaria
02/04/2026
Phase II
A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)
2025-522440-41-00Hidradenitis Suppurativa
Bluefin Biomedicine Inc.
Skin and Connective Tissue Diseases
Spain, Germany, Czechia, Poland, Bulgaria
31/03/2026
Phase III
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS trial)
2025-521936-12-00Adults with Type 2 Diabetes and/or Metabolic Syndrome on gโ€ฆ
NewAmsterdam Pharma B.V.
Cardiovascular Diseases
Czechia, Slovakia, Netherlands
31/03/2026
Phase IV
Identification of mitochondrial biomarkers reflecting omaveloxolone treatment (in FA patients)
2025-523881-26-00Friedreich's ataxia
Fakultni Nemocnice V Motole
Nervous System Diseases
Czechia, Poland
30/03/2026
Phase III
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants with Diabetic Macular Edema (DME) (EYP-1901-304)
2025-523938-10-00Diabetic Macular Edema (DME)
Eyepoint Inc.
Eye Diseases
Hungary, Czechia, Germany
30/03/2026
Phase I
Bioequivalence study 2 to compare pharmacokinetics of Parkinsonยดs disease drugs in healthy volunteers
2026-525449-57-00Parkinson desease
Orion Corporation
Nervous System Diseases
Czechia
27/03/2026
Phase III
Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 Versus Investigatorโ€™s Choice Chemotherapy in FRฮฑ-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
2025-520466-22-00Advanced Platinum-resistant Epithelial Ovarian Cancer
AstraZeneca AB
Pathological Conditions, Signs and Symptoms
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany
27/03/2026
Phase III
J3R-MC-YDAF - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Obesity or Overweight, and Type 2 Diabetes
2025-523658-15-00Obesity, Overweight
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Germany, Spain, Poland, Czechia, Slovakia
24/03/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction
2025-522475-28-00Pulmonary Hypertension (PH) with Heart Failure with preservโ€ฆ
Tenax Therapeutics Inc.
Cardiovascular Diseases
France, Italy, Germany, Czechia, Austria, Poland, Hungary, Bulgaria, Spain
24/03/2026
Phase III
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
2025-523461-17-01LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Pfizer Inc.
Neoplasms
France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany
24/03/2026
Phase II
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants with Active Psoriatic Arthritis
2025-523141-10-00Active Psoriatic Arthritis
Janssen Cilag International
Immune System Diseases
Spain, Poland, Czechia, Germany, Hungary
20/03/2026
Phase II
Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay
2025-524553-13-00lung and/or heart failure
Fakultni Nemocnice Ostrava
Cardiovascular Diseases
Czechia
19/03/2026
Phase IV
Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates
2026-526044-12-00Obesity
Institute For Clinical And Experimental Medicine
Digestive System Diseases
Czechia
18/03/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension
2024-514754-79-00Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Belgium, France, Poland, Germany, Spain, Czechia
18/03/2026
Phase II
Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children โ€“ open-label phase II clinical trial (FMT-PAS)
2025-524673-16-00Autism spectrum disorder
Masarykova Univerzita
Nervous System Diseases
Czechia
17/03/2026
Phase II
An open-label, uncontrolled, multicenter study to assess the effect of zigakibart treatment on histologic, circulating, and excreted markers of kidney disease and dysfunction in adult patients with IgA nephropathy
2024-519699-24-00IgA nephropathy
Novartis Pharma AG
Immune System Diseases
Czechia, Germany, Spain, Italy, Poland
17/03/2026
Phase I/II
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00progressive/relapsed/refractory pediatric low-grade glioma โ€ฆ
Universitaetsklinikum Heidelberg AรถR
Nervous System Diseases
Denmark, Czechia, Austria, Sweden, Germany
17/03/2026
Phase III
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)
2025-522878-36-00Chronic Spontaneous Urticaria
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase I
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults
2025-522782-30-00CCI
UCB Biopharma
Immune System Diseases
Croatia, Poland, Germany, Czechia, Slovakia, Bulgaria
16/03/2026
Phase III
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
2024-517943-29-00Pulmonary Hypertension associated with interstitial lung diโ€ฆ
Liquidia Technologies Inc.
Respiratory Tract Diseases
Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain
11/03/2026
Phase I
Bioequivalence Study of Empagliflozin
2026-525434-33-00Not applicable (submitted trial is a BE study in healthy paโ€ฆ
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Nutritional and Metabolic Diseases
Czechia
11/03/2026
Phase II
A Phase II, multinational, multicentre, double-blind, randomised, active-controlled, 3-way cross-over study to evaluate the therapeutic equivalence of CHF5993 pMDI 100/6/12.5 ยตg HFA-152a versus CHF5993 pMDI 100/6/12.5 ยตg HFA-134a in subjects with mild to moderate asthma. [TRECONY]
2025-521456-35-00Mild to moderate asthma
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Slovakia, Czechia, Romania, Latvia, Germany, Hungary, Bulgaria, Poland
11/03/2026
Phase III
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
2025-523224-45-00Untreated, Unresectable or Metastatic Colorectal Cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria
10/03/2026
Phase II
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
2025-522578-35-00Atopic Dermatitis
UCB Biopharma
Skin and Connective Tissue Diseases
Bulgaria, Czechia, Germany, Poland, Hungary
09/03/2026
Phase II
A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohnโ€™s disease or ulcerative colitis
2025-522511-42-00Crohn's disease, Colitis Ulcerative
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase III
A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea High Dose (HD) in Participants with Diabetic Macular Edema (ALVOEYE-HD)
2025-522231-34-00Diabetic Macular Edema
Alvotech Swiss AG
Eye Diseases
Latvia, Slovakia, Czechia, Hungary, Poland, Bulgaria
06/03/2026
Phase I
Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.
2026-525256-29-00Comparative bioavailability study under fasting conditions
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
04/03/2026
Phase III
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
2025-521884-12-00First line triple-negative breast cancer (TNBC)
BioNTech SE
Neoplasms
Czechia, Poland, Italy, France, Belgium, Netherlands, Germany, Spain
04/03/2026
Phase III
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
2025-521546-23-00Secondary progressive multiple sclerosis
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase III
A prospective, open-label, single-arm, multicenter study evaluating the efficacy of Xanomeline/Trospium (XT) on cognitive impairment after 24 and 52 weeks of treatment in adult participants with schizophrenia.
2025-523060-20-00Schizophrenia
European Group for Research in Schizophrenia Stichting
Mental Disorders
Denmark, Belgium, Italy, Netherlands, Hungary, Czechia, Austria, Spain, Germany
03/03/2026
Phase III
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00psoriatic arthritis (PsA)
MoonLake Immunotherapeutics AG
Musculoskeletal Diseases
Estonia, Croatia, Slovakia, Lithuania, Romania, Hungary, Germany, France, Latvia, Poland, Portugal, Greece, Czechia, Bulgaria, Finland, Spain
25/02/2026
Phase II
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults with Major Depressive Disorder
2025-522784-15-00Major Depressive Disorder
Draig Therapeutics Limited
Mental Disorders
Czechia, Bulgaria, Poland
24/02/2026
Phase III
J2A-MC-GZPW: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
2025-523123-22-00Atherosclerosis Cardiovascular Disease, Chronic Kidney Diseโ€ฆ
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohnโ€™s disease
2025-521037-86-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohnโ€™s Disease
2025-521036-11-00Immune system disseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase III
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients
2025-521521-33-00Kidney transplant rejection
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase III
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
2025-521314-25-00NPM1-m and KMT2A-r Acute Myeloid Leukemia
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase I
A bioequivalence study comparing Empagliflozin 25 mg film-coated tablets, VIANEX S.A., Greece versus Jardiance 25 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2025-524910-28-00none - healthy volunteers
Vianex S.A.
Cardiovascular Diseases
Czechia
18/02/2026
Phase III
A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)
2025-522873-12-00ER+, HER2- Advanced Breast Cancer
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase II
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
2025-521390-14-00Acute Myeloid Leukemia
Pediatric Research International GmbH
Neoplasms
Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria
16/02/2026
Phase I
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
2025-523826-41-00Dermatitis atopic
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, France, Hungary, Poland, Spain, Bulgaria
16/02/2026
Phase III
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
2025-523533-25-00Cancer-associated Cachexia
CatalYm GmbH
Nutritional and Metabolic Diseases
France, Czechia, Romania, Italy, Germany, Poland, Spain, Bulgaria, Norway, Ireland, Netherlands
13/02/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)
2025-522279-27-00Newly Diagnosed AML with an NPM1 mutation
Syndax Pharmaceuticals Inc.
Neoplasms
Greece, Poland, Spain, Austria, Italy, Romania, Belgium, France, Lithuania, Germany, Hungary, Czechia, Portugal
13/02/2026
Phase I
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
2025-521732-11-00No medical condition
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
12/02/2026
Phase III
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00Metastatic colorectal cancer
Summit Therapeutics Inc.
Neoplasms
Belgium, Italy, Spain, Germany, France, Poland, Czechia, Hungary
12/02/2026
Rows per page Showing 101–200 of 331
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-europe/country/czechia?page=2

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,479 trial records at the last sync on 24 Sep 2026, 03:17 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 331 of those trials with a site in Czechia.

How many recently authorised EU trials have a site in Czechia?

331 of the 2,500 most recently authorised trials in this register list a site in Czechia; 200 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.